Drug intelligence / Profile preview

AD13

Development stage: Preclinical
Lead developer: ADvantage Therapeutics

Overview

AD13 is a preclinical-stage drug candidate being developed by ADvantage Therapeutics for the treatment of neurodegenerative diseases, including Alzheimer's disease. As part of ADvantage Therapeutics' pipeline, which focuses on neuro-immunology and the modulation of the body's immune response to treat brain disorders, AD13 represents an early-stage asset aimed at addressing the underlying pathology of cognitive decline. While specific details regarding its molecular target, chemical structure, and exact mechanism of action have not been publicly disclosed, the program aligns with the company's mission to develop therapies that regulate neuroinflammation and microglial activity.

Beyond the preview

Go deeper on AD13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD13.

Explore the full profile